에이디셋바이오ACET 주가

[10-K/A] 10-K/A — 10-K/A

[SCHEDULE 13G/A] SCHEDULE 13G/A

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 14, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

REDWOOD CITY, Calif., May 13, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026.

Adicet Bio Q1 EPS $(1.88) Beats $(3.21) Estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(3.21) by 41.43 percent. This is a 62.1 percent increase over losses of $(4.96) per share from the

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

[S-8 POS] S-8 POS — S-8 POS

[4] 내부자 거래

[ARS] ARS — ARS